Vanguard Global Advisers’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$168K Buy
17,305
+226
+1% +$2.62K ﹤0.01% 2548
2026
Q2
$199K Sell
17,079
-2,581
-13% -$36.8K ﹤0.01% 2503
2026
Q1
$330K Buy
+19,660
New +$352K ﹤0.01% 2212

Other funds holding CLB

Vanguard Global Advisers's CLB Position: Q3 2026 in Review

Vanguard Global Advisers increased its Core Laboratories (CLB) stake by 1.3% in Q3 2026, buying an estimated $2.62K and bringing the position to 17,305 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #2548.

Vanguard Global Advisers first reported a position in CLB in Q1 2026 and has held it in 3 quarters since. The position peaked at $330K in Q1 2026. 179 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • Vanguard Global Advisers held 17,305 shares of Core Laboratories worth $168K as of Q3 2026.
  • Vanguard Global Advisers bought 226 Core Laboratories shares in Q3 2026, an estimated $2.62K.
  • Core Laboratories made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2548 holding.
  • Vanguard Global Advisers first reported a position in Core Laboratories in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Core Laboratories position peaked at $330K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.